[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,089,780
  • Shares Outstanding, K 223,985
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 225 M
  • EBITDA $ 233 M
  • 60-Month Beta 0.78
  • Price/Sales 4.12
  • Price/Cash Flow 14.28
  • Price/Book 5.16

Options Overview Details

View History
  • Implied Volatility 51.33% (+2.30%)
  • Historical Volatility 42.45%
  • IV Percentile 13%
  • IV Rank 11.61%
  • IV High 147.60% on 03/27/26
  • IV Low 38.69% on 08/26/26
  • Expected Move (DTE 16) 0.70 (7.47%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 149
  • Volume Avg (30-Day) 784
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 54,644
  • Open Int (30-Day) 66,425
  • Expected Range 8.63 to 10.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.19
  • Number of Estimates 1
  • High Estimate $0.19
  • Low Estimate $0.19
  • Prior Year $0.16
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.57 +8.87%
on 08/03/26
10.35 -9.86%
on 08/06/26
+0.87 (+10.28%)
since 07/31/26
3-Month
7.45 +25.23%
on 06/02/26
10.35 -9.86%
on 08/06/26
+1.43 (+18.10%)
since 06/01/26
52-Week
7.21 +29.40%
on 03/26/26
20.46 -54.39%
on 12/12/25
-7.93 (-45.94%)
since 08/29/25

Most Recent Stories

More News
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PHILADELPHIA , Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  announces an investigation into potential breaches of fiduciary duty by the Board of Directors...

ADMA : 9.33 (-0.64%)
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

LOS ANGELES , Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA ) for violations...

ADMA : 9.33 (-0.64%)
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PHILADELPHIA , Aug. 17, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  announces an investigation into potential breaches of fiduciary duty by the Board of Directors...

ADMA : 9.33 (-0.64%)
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK , Aug. 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and...

ADMA : 9.33 (-0.64%)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (“ADMA” or “the Company”)...

ADMA : 9.33 (-0.64%)
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss...

ADMA : 9.33 (-0.64%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline

SAN FRANCISCO , Aug. 10, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA)  that a securities fraud class action lawsuit has been filed. The lawsuit...

ADMA : 9.33 (-0.64%)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES , Aug. 10, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP  ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics,...

ADMA : 9.33 (-0.64%)
DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026

SAN FRANCISCO , Aug. 9, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA)  that a securities fraud class action lawsuit has been filed. The lawsuit...

ADMA : 9.33 (-0.64%)
ADMA Biologics 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 10, 2026 ...

ADMA : 9.33 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 9.68
2nd Resistance Point 9.59
1st Resistance Point 9.46
Last Price 9.33
1st Support Level 9.24
2nd Support Level 9.16
3rd Support Level 9.03

See More

52-Week High 20.46
Fibonacci 61.8% 15.40
Fibonacci 50% 13.83
Fibonacci 38.2% 12.27
Last Price 9.33
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.